These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 29807757)

  • 1. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
    Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients-A Potentially Increased Sensitivity of Thrombi to Lysis?
    Pretnar Oblak J; Sabovic M; Frol S
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):768-773. PubMed ID: 30527792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke - a single centre experience.
    Włodarczyk E; Sawczyńska K; Wrona P; Słowik A
    Neurol Neurochir Pol; 2023; 57(6):465-476. PubMed ID: 37955597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.
    Berrouschot J; Stoll A; Hogh T; Eschenfelder CC
    Stroke; 2016 Jul; 47(7):1936-8. PubMed ID: 27301937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
    Li M; Wang-Qin RQ; Wang YL; Liu LB; Pan YS; Liao XL; Wang YJ; Xu AD
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1235-43. PubMed ID: 25891755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study.
    Zand R; Tsivgoulis G; Sadighi A; Singh M; McCormack M; Shahjouei S; Goyal N; Noorbakhsh-Sabet N; Alexandrov AW; Alexandrov AV
    J Stroke Cerebrovasc Dis; 2018 Mar; 27(3):620-624. PubMed ID: 29100859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].
    Pásztor M; Bereczki D; Szakács Z; May Z
    Ideggyogy Sz; 2017 Jul; 70(7-8):284-288. PubMed ID: 29870643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.
    Pikija S; Sztriha LK; Sebastian Mutzenbach J; Golaszewski SM; Sellner J
    CNS Drugs; 2017 Sep; 31(9):747-757. PubMed ID: 28808918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Althaus K; Berrouschot J; Cangür H; Daffertshofer M; Edelbusch S; Gröschel K; Haase CG; Harloff A; Held V; Kauert A; Kraft P; Lenz A; Müllges W; Obermann M; Partowi S; Purrucker J; Ringleb PA; Röther J; Rossi R; Schäfer N; Schneider A; Schuppner R; Seitz RJ; Szabo K; Wruck R
    Int J Stroke; 2017 Jun; 12(4):383-391. PubMed ID: 28494694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of intravenous thrombolysis with recombinant tissue plasminogen activator in eighty years and older acute ischemic stroke patients.
    Chen Y; Li CH; Wang YX; Zhang CH; Dong Z; Zhang FF; Wang JH; Zhang PL
    Eur Rev Med Pharmacol Sci; 2015 May; 19(10):1852-8. PubMed ID: 26044231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis in stroke mimics: results from the SITS International Stroke Thrombolysis Register.
    Keselman B; Cooray C; Vanhooren G; Bassi P; Consoli D; Nichelli P; Peeters A; Sanak D; Zini A; Wahlgren N; Ahmed N; Mazya MV
    Eur J Neurol; 2019 Aug; 26(8):1091-1097. PubMed ID: 30793434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
    Tireli D; He J; Nordling MM; Wienecke T
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revascularization outcomes following acute ischemic stroke in patients taking direct oral anticoagulants: a single hospital cohort study.
    Frol S; Šabovič M; Popovič KŠ; Oblak JP
    J Thromb Thrombolysis; 2021 Jan; 51(1):194-202. PubMed ID: 32506363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
    Ohtani T; Sintoku R; Yajima T; Kaneko N
    J Med Case Rep; 2019 Dec; 13(1):390. PubMed ID: 31875786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
    Meyer D; Chu F; Derry K; Hailey L
    J Clin Neurosci; 2019 Jan; 59():355-357. PubMed ID: 30309801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
    Kermer P; Eschenfelder CC; Diener HC; Grond M; Abdalla Y; Abraham A; Althaus K; Becks G; Berrouschot J; Berthel J; Bode FJ; Burghaus L; Cangür H; Daffertshofer M; Edelbusch S; Eggers J; Gerlach R; Gröschel K; Große-Dresselhaus F; Günther A; Haase CG; Haensch CA; Harloff A; Heckmann JG; Held V; Hieber M; Kauert A; Kern R; Kerz T; Köhrmann M; Kraft P; Kühnlein P; Latta J; Leinisch E; Lenz A; Leithner C; Neumann-Haefelin T; Mäurer M; Müllges W; Nolte CH; Obermann M; Partowi S; Patzschke P; Poli S; Pulkowski U; Purrucker J; Rehfeldt T; Ringleb PA; Röther J; Rossi R; El-Sabassy H; Sauer O; Schackert G; Schäfer N; Schellinger PD; Schneider A; Schuppner R; Schwab S; Schwarte O; Seitz RJ; Senger S; Shah YP; Sindern E; Sparenberg P; Steiner T; Szabo K; Urbanek C; Sarnowksi BV; Weissenborn K; Wienecke P; Witt K; Wruck R; Wunderlich S
    Int J Stroke; 2020 Aug; 15(6):609-618. PubMed ID: 31955706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.